Polypharmacology as an Emerging Trend in Antibacterial Discovery

Polypharmacology in Drug Discovery

Volumn , Issue , 2012, Pages 167-202

  Silver, Lynn L ^a  

^a LL Silver Consulting LLC   (United States)

Author keywords

Hybrid molecules, and synthetic polypharmacy; Inhibitors of protein synthesis targeting rRNA; Multitargeted single pharmacophores

Indexed keywords

EID: 84886067399     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118098141.ch9     Document Type: Chapter

References (153)

1. Cohen, S. S. (1977), A strategy for the chemotherapy of infectious disease, Science 197, 431-432.
2. Silver, L. L. (2007), Multi-targeting by monotherapeutic antibacterials, Nature Rev. Drug Discov. 6, 41-55.
3. Blumberg, P. M.; Strominger, J. L. (1974), Interaction of penicillin with the bacterial cell: Penicillin-binding proteins and penicillin-sensitive enzymes, Bacteriol. Rev. 38, 291-335.
4. Spratt, B. G. (1975), Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12, Proc. Nat. Acad. Sci. USA 72, 2999-3003.
5. Silver, L.; Bostian, K. (1990), Screening of natural products for antimicrobial agents, Eur. J. Clin. Microbiol. Infect. Dis. 9, 455-461.
6. Silver, L. L.; Bostian, K. A. (1993), Discovery and development of new antibiotics: The problem of antibiotic resistance, Antimicrob. Agents Chemother. 37, 377-383.
7. Ferrero, L.; Cameron, B.; Manse, B.; Lagneaux, D.; Crouzet, J.; Famechon, A.; Blanche, F. (1994), Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones, Mol. Microbiol. 13, 641-653.
8. Khodursky, A. B.; Zechiedrich, E. L.; Cozzarelli, N. R. (1995), Topoisomerase IV is a target of quinolones in Escherichia coli, Proc. Natl. Acad. Sci. USA 92, 11801-11805.
9. Brotz-Oesterhelt, H.; Brunner, N. A. (2008), How many modes of action should an antibiotic have? Curr. Opin. Pharmacol. 8, 564-573.
10. Lange, R. P.; Locher, H. H.;Wyss, P. C.; Then, R. L. (2007), The targets of currently used antibacterial agents: Lessons for drug discovery, Curr. Pharm. Design 13, 3140-3154.
11. Spratt, B. G. (1994), Resistance to antibiotics mediated by target alterations, Science 264, 388-393.
12. Chopra, I. (1998), Research and development of antibacterial agents, Curr. Opin. Microbiol. 1, 495-501.
13. Hooper,D. (2001), Minimizing potential resistance: The molecular view-acomment on Courvalin and Trieu-Cuot, Clin. Infect. Dis. 33, S157-S160.
14. Guay, D. R. (2007), Drug forecast-the peptide deformylase inhibitors as antibacterial agents, Ther. Clin. Risk Manage. 3, 513-525.
15. Freund, Y.; Kimura, R.; Baker, S. J.; Mendes, R. E.; Biedenbach, D. J.; Simon, N. L.; Demarsh, P. L.; O'leary, A.; Alley,M. R. K., In vitro activity and in vivo efficacy of (S)-3 (aminomethyl)benzo[c][1,2]oxaborol-1(3H)-ol hydrochloride compound: A gramnegative antimicrobial, Proc. 49th Interscience Conf. Antimicrobial Agents Chemotherapy, Chicago, 2009.
16. Andersson, D. I.; Levin, B. R. (1999), The biological cost of antibiotic resistance, Curr. Opin. Microbiol. 2, 489-493.
17. Andersson, D. I. (2006), The biological cost of mutational antibiotic resistance: Any practical conclusions? Curr. Opin. Microbiol. 9, 461-465.
18. Bjorkman, J.; Nagaev, I.; Berg, O. G.; Hughes, D.; Andersson, D. I. (2000), Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance, Science 287, 1479-1482.
19. Hawser, S.; Lociuro, S.; Islam, K. (2006), Dihydrofolate reductase inhibitors as antibacterial agents, Biochem. Pharmacol 71, 941-948.
20. Gilbert, D. N.; Moellering, R. C.; Eliopoulos, G. M.; Chambers, H. F.; Saag, M. S., eds., The Sanford Guide to Antimicrobial Therapy, Antimicrobial Therapy, Inc. , Sperryville, VA, 2009, pp. 35-38.
21. Blumberg, P. M.; Yocum, R. R.; Willoughby, E.; Strominger, J. L. (1974), Binding of (14C)penicillin G to the membrane-bound and the purified D-alanine carboxypeptidases from Bacillus stearothermophilus and Bacillus subtilis and its release, J. Biol. Chem. 249, 6828-6835.
22. Strominger, J. L.; Willoughby, E.; Kamiryo, T.; Blumberg, P. M.; Yocum, R. R. (1974), Penicillin-sensitive enzymes and penicillin-binding components in bacterial cells, Ann. NY Acad. Sci. 235, 210-224.
23. Goffin, C.; Ghuysen, J.-M. (1998), Multimodular penicillin-binding proteins: An enigmatic family of orthologs and paralogs, Microbiol. Mol. Biol. Rev. 62, 1079-1093.
24. Georgopapadakou, N. H.; Liu, F. Y. (1980), Penicillin-binding proteins in bacteria, Antimicrob. Agents Chemother. 18, 148-157.
25. Denome, S. A.; Elf, P. K.; Henderson, T. A., Nelson, D. E.; Young, K. D. (1999), Escherichia coli mutants lacking all possible combinations of eight penicillin binding proteins: Viability, characteristics, and implications for peptidoglycan synthesis, J. Bacteriol. 181, 3981-3993.
26. Spratt, B. G. (1977), Temperature-sensitive cell division mutants of Escherichia coli with thermolabile penicillin-binding proteins, J. Bacteriol. 131, 293-305.
27. Yousif, S. Y.; Broome-Smith, J. K.; Spratt, B. G. (1985), Lysis of Escherichia coli by β-lactam antibiotics: Deletion analysis of the role of penicillin-binding proteins 1A and 1B J. Gen. Microbiol. 131, 2839-2845.
28. Severin, A.;Vaz Pato, M.V.; Sà Figueiredo, A. M.; Tomasz, A. (1995), Drastic changes in the peptidoglycan composition of penicillin resistant laboratory mutants of Streptococcus pneumoniae, FEMS Microbiol. Lett. 130, 31-35.
29. Spratt, B. G.; Bowler, L. D.; Zhang, Q.-Y.; Zhou, J.; Smith, J. M. (1992), Role of interspecies transfer of chromosomal genes in the evolution of penicillin resistance in pathogenic and commensal Neisseria species, J. Mol. Evol. 34, 115-125.
30. Macheboeuf, P.; Fischer, D. S.; Brown, T., Jr.; Zervosen, A.; Luxen, A.; Joris, B.; Dessen, A.; Schofield, C. J. (2007), Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins, Nature Chem Biol. 3, 565-569.
31. Zervosen, A.; Lu, W. P.; Chen, Z.; White, R. E.; Demuth, T. P., Jr.; Frere, J. M. (2004), Interactions between penicillin-binding proteins (PBPs) and two novel classes of PBP inhibitors, arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones, Antimicrob. Agents Chemother. 48, 961-969.
32. Pechenov, A.; Stefanova, M. E.; Nicholas, R. A.; Peddi, S.; Gutheil, W. G. (2003), Potential transition state analogue inhibitors for the penicillin-binding proteins, Biochemistry 42, 579-588.
33. Xing, B.; Rao, J.; Liu, R. (2008), Novel β-lactam antibiotics derivatives: Their new applications as gene reporters, antitumor prodrugs and enzyme inhibitors, Mini Rev. Med. Chem. 8, 455-471.
34. Hooper,D. C. (1998), Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance, Clin. Infect. Dis. 27, S54-S63.
35. Gellert, M.; Mizuuchi, K.; O'dea, M. H.; Nash, H. A. (1976), DNA gyrase: An enzyme that Introduces superhelical turns into DNA, Proc. Natl. Acad. Sci. USA 73, 3872-3876.
36. Kato, J.; Nishimura, Y.; Imamura, R.; Niki, H.; Hiraga, S.; Suzuki, H. (1990), New topoisomerase essential for chromosome segregation in E. coli, Cell 63, 393-404.
37. Deitz,W. H.; Bailey, J. H.; Froelich, E. (1963), In vitro antibacterial properties of nalidixic acid, a newdrug active against gram negative organisms, Antimicrob. Agents Chemother. 161, 583-587.
38. Slade, D. A. (1963), A clinical trial of nalidixic acid (Negram, WIN. 18,320) in thirty-three patients with urinary infections treated in general practice, Br. J. Urol. 35, 125-128.
39. Ng, E. Y., Trucksis, M.; Hooper, D. C. (1996), Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus, Antimicrob. Agents Chemother. 40, 1881-1888.
40. Zhao, X.; Xu, C.; Domagala, J.; Drlica, K. (1997), DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance, Proc. Natl. Acad. Sci. USA 94, 13991-13996.
41. Takei, M.; Fukuda, H.; Kishii, R.; Hosaka, M. (2001), Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition, Antimicrob. Agents Chemother. 45, 3544-3547.
42. Strahilevitz, J.; Hooper, D. C. (2005), Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: Direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin, Antimicrob. Agents Chemother. 49, 1949-1956.
43. Hane, M. W.; Wood, T. H. (1969), Escherichia coli K-12 mutants resistant to nalidixic acid: Genetic mapping and dominance studies, J. Bacteriol. 99, 238-241.
44. Kreuzer, K. N.; Cozzarelli, N. R. (1979), Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth, J. Bacteriol. 140, 424-435.
45. Ince, D.; Hooper, D. C. (2003), Quinolone resistance due to reduced target enzyme expression, J. Bacteriol. 185, 6883-6892.
46. Khodursky, A. B.; Cozzarelli, N. R. (1998), The mechanism of inhibition of topoisomerase IV by quinolone antibacterials, J. Biol. Chem. 273, 27668-27677.
47. Drlica, K.; Zhao, X. (1997), DNA gyrase, topoisomerase IV, and the 4-quinolones, Microbiol. Mol. Biol. Rev. 61, 377-392.
48. Strominger, J. L.; Ito, E.; Threnn, R. H. (1960), Competitve inhibition of enzymatic reactions by oxamycin, J. Am. Chem. Soc. 82, 998-999.
49. Caceres, N. E.; Harris, N. B.;Wellehan, J. F.; Feng, Z.; Kapur, V.; Barletta, R. G. (1997), Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis, J. Bacteriol. 179, 5046-5055.
50. Halouska, S.; Chacon, O.; Fenton, R. J.; Zinniel, D. K.; Barletta, R. G.; Powers, R. (2007), Use ofNMRmetabolomics to analyze the targets of D-cycloserine in mycobacteria: Role of D-alanine racemase, J. Proteome Res. 6, 4608-4614.
51. Cundliffe, E. (1987), On the nature of antibiotic binding sites in ribosomes, Biochimie 69, 863-869.
52. Wilson, D. N. (2009), The A-Z of bacterial translation inhibitors, Crit. Rev. Biochem. Mol. Biol. 44, 393-433.
53. Bercovier, H.; Kafri, O.; Sela, S. (1986), Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome, Biochem. Biophys. Res. Commun. 136, 1136-1141.
54. Marshall, S. H.; Donskey, C. J.; Hutton-Thomas, R.; Salata, R. A.; Rice, L. B. (2002), Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis, Antimicrob. Agents Chemother. 46, 3334-3336.
55. Prystowsky, J.; Siddiqui, F.; Chosay, J.; Shinabarger, D. L.; Millichap, J.; Peterson, L. R.; Noskin, G. A. (2001), Resistance to linezolid: Characterization of mutations in rRNAand comparison of their occurrences in vancomycin-resistant enterococci, Antimicrob. Agents Chemother. 45, 2154-2156.
56. Sigmund, C. D.; Ettayebi, M.; Morgan, E. A. (1984), Antibiotic resistance mutations in 16S and 23S ribosomal RNA genes of Escherichia coli, Nucl. Acids Res. 12, 4653-4664.
57. Garza-Ramos, G.; Xiong, L.; Zhong, P.; Mankin, A. (2001), Binding site of macrolide antibiotics on the ribosome: New resistance mutation identifies a specific interaction of ketolides with rRNA, J. Bacteriol. 183, 6898-6907.
58. Asai, T.; Zaporojets, D.; Squires, C.; Squires, C. L. (1999), An Escherichia coli strain with all chromosomal rRNA operons inactivated: Complete exchange of rRNA genes between bacteria, Proc. Natl. Acad. Sci. USA 96, 1971-1976.
59. Bauer, G.; Berens, C.; Projan, S. J.; Hillen, W. (2004), Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA, J. Antimicrob. Chemother. 53, 592-599.
60. Smith, D. H.; Davis, B. D. (1967), Mode of action of novobiocin in Escherichia coli, J. Bacteriol. 93, 71-79.
61. Gellert, M.; O'dea, M. H.; Itoh, T.; Tomizawa, J. (1976), Novobiocin and coumermycin inhibitDNAsupercoiling catalyzed byDNAgyrase, Proc. Natl. Acad. Sci. USA 73, 4474-4478.
62. Sugino, A.; Higgins, N. P.; Brown, P. O.; Peebles, C. L.; Cozzarelli, N. R. (1978), Energy coupling in DNA gyrase and the mechanism of action of novobiocin, Proc. Natl. Acad. Sci. USA 75, 4838-4842.
63. Arathoon, E. G., Hamilton, J. R.; Hench, C. E.; Stevens, D. A. (1990), Efficacy of short courses of oral novobiocin-rifampin in eradicating carrier state of methicillin-resistant Staphylococcus aureus and in vitro killing studies of clinical isolates, Antimicrob. Agents Chemother. 34, 1655-1659.
64. Walsh, T. J.; Standiford, H. C.; Reboli, A. C.; John, J. F.; Mulligan, M. E.; Ribner, B. S.; Montgomerie, J. Z.; Goetz, M. B.; Mayhall, C. G.; Rimland, D.; et al. (1993), Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: Prevention of antimicrobial resistance and effect of host factors on outcome, Antimicrob. Agents Chemother. 37, 1334-1342.
65. Gal, K. (1965), Combined antibiotic therapy, Can. Med. Assoc. J. 93, 1225.
66. Barber, M.; Dutton, A. A.; Beard, M. A.; Elmes, P. C.; Williams, R. (1960), Reversal of antibiotic resistance in hospital staphylococcal infection, Br. Med. J. 1, 11-17.
67. Bellon, S.; Parsons, J. D.; Wei, Y.; Hayakawa, K.; Swenson, L. L.; Charifson, P. S.; Lippke, J. A.; Aldape, R.; Gross, C. H. (2004), Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): A single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase, Antimicrob. Agents Chemother. 48, 1856-1864.
68. Fujimoto-Nakamura, M.; Ito, H.; Oyamada, Y.; Nishino, T.; Yamagishi, J.-I. (2005), Accumulation of mutations in both gyrB and parE genes Is associated with high-level resistance to novobiocin in Staphylococcus aureus, Antimicrob. Agents Chemother. 49, 3810-3815.
69. Flatman, R. H.; Eustaquio, A.; Li, S. M.; Heide, L.; Maxwell, A. (2006), Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IVinhibitors obtained by combinatorial biosynthesis, Antimicrob. Agents Chemother. 50, 1136-1142.
70. Charifson, P. S.; Grillot, A. L.; Grossman, T. H.; Parsons, J. D.; Badia, M.; Bellon, S.; Deininger, D. D.; Drumm, J. E.; Gross, C. H.; Letiran, A.; Liao, Y.; Mani, N.; Nicolau, D. P.; Perola, E.; Ronkin, S.; Shannon, D.; Swenson, L. L.; Tang, Q.; Tessier, P. R.; Tian, S. K.; Trudeau, M.; Wang, T.; Wei, Y.; Zhang, H.; Stamos, D. (2008), Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships, J. Med. Chem. 51, 5243-5263.
71. Charifson, P. S.; Grossman, T. H.; Mueller, P. (2009), The use of structure-guided design to discover new anti-microbial agents: Focus on antibacterial resistance, Anti-Infect. Agents Med. Chem. 8, 73-86.
72. Grossman, T. H.; Bartels, D. J.; Mullin, S.; Gross, C. H.; Parsons, J. D.; Liao, Y.; Grillot, A. L.; Stamos, D.; Olson, E. R.; Charifson, P. S.; Mani, N. (2007), Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds, Antimicrob. Agents Chemother. 51, 657-666.
73. East, S. P.; White, C. B.; Barker, O.; Barker, S.; Bennett, J.; Brown, D.; Boyd, E. A.; Brennan, C.; Chowdhury, C.; Collins, I.; Convers-Reignier, E.; Dymock, B.W.; Fletcher, R.; Haydon, D. J.; Gardiner, M.; Hatcher, S.; Ingram, P.; Lancett, P.; Mortenson, P.; Papadopoulos, K.; Smee, C.; Thomaides-Brears, H. B.; Tye, H.; Workman, J.; Czaplewski, L. G. (2009), DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity, Bioorg. Med. Chem. Lett. 19, 894-899.
74. Wiener, J. J.; Gomez, L.;Venkatesan, H.; Santillan, A., Jr.; Allison, B. D.; Schwarz, K. L.; Shinde, S.; Tang, L.; Hack, M. D.; Morrow, B. J.; Motley, S.T.; Goldschmidt, R. M.; Shaw, K. J.; Jones, T. K.; Grice, C. A. (2007), Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains, Bioorg. Med. Chem. Lett. 17, 2718-2722.
75. Bradbury, B. J.; Pucci, M. J. (2008), Recent advances in bacterial topoisomerase inhibitors, Curr. Opin. Pharmacol. 8, 574-581.
76. Oblak, M.; Kotnik, M., Solmajer, T. (2007), Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents, Curr. Med. Chem. 14, 2033-2047.
77. Cheng, J.;Thanassi, J.A.;Thoma,C.L.;Bradbury,B. J.;Deshpande,M.;Pucci,M. J. (2007), Dual targeting of DNA gyrase and topoisomerase IV: Target interactions of heteroaryl isothiazolones in Staphylococcus aureus, Antimicrob. Agents Chemother. 51, 2445-2453.
78. Molina-Torres, C. A.; Ocampo-Candiani, J.; Rendon, A.; Pucci, M. J.; Vera-Cabrera, L. (2010), In vitro activity of a newisothiazoloquinolone,ACH-702, against Mycobacterium tuberculosis and other mycobacteria, Antimicrob. Agents Chemother. 54, 2188-2190.
79. Huband, M. D.; Cohen, M. A.; Zurack, M.; Hanna, D. L.; Skerlos, L. A.; Sulavik, M. C.; Gibson, G.W.; Gage, J.W.; Ellsworth, E.; Stier,M. A.; Gracheck, S. J. (2007), In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups, Antimicrob. Agents Chemother. 51, 1191-1201.
80. Pan, X.-S.; Gould, K. A.; Fisher, L. M. (2009), Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV, Antimicrob. Agents Chemother. 53, 3822-3831.
81. Brown, N. C.; Handschumacher, R. E. (1966), Inhibition of the synthesis of deoxyribonucleic acid in bacteria by 6-(p-hydroxyphenylazo)-2,4-dihydroxypyrimidine, I. Metabolic studies in Streptococcus faecalis, J. Biol. Chem. 241, 3083-3089.
82. Brown, N. C. (1971), Inhibition of bacterial DNA replication by 6-(p-hydroxyphenylazo)-uracil: Differential effect on repair and semi-conservative synthesis in Bacillus subtilis, J. Mol. Biol. 59, 1-16.
83. Mackenzie, J. M.; Neville, M. M.; Wright, G. E.; Brown, N. C. (1973), Hydroxyphenylazopyrimidines: Characterization of the active forms and their inhibitory action on a DNA polymerase from Bacillus subtilis, Proc. Natl. Acad. Sci. USA 70, 512-516.
84. Barnes, M. H.; Brown, N. C. (1979), Antibody to B. subtilis DNA polymerase III: Use in enzyme purification and examination of homology among replication-specific DNA polymerases, Nucl. Acids Res. 6, 1203-1219.
85. Wright, G.; Brown, N. (1974), Synthesis of 6-(phenylhydrazino)uracils and their inhibition of a replication-specific deoxyribonucleic acid polymerase, J. Med. Chem. 17, 1277-1282.
86. Brown, N.; Wright, G., DNAPolymerase III of B. subtilis: Characterization of the binding site for arylhydrazinopyrimidine inhibitors, in Molineux, I.; Kohiyama, M., eds., Proc. NATO Advanced Study Institute-DNA Synthesis: Present and Future, Plenum Press, NewYork London, 1978, pp. 467-477.
87. Wright, G.; Brown, N. (1980), Inhibitors of Bacillus subtilis DNA Polymerase 111 6-anilinouracils and 6-(alkylamino) uracils, J. Med. Chem. 23, 34-38.
88. Ali, A.; Taylor, G. E. (2005), Development of DNA polymerase IIIC inhibitors for the treatment of gram-positive bacterial infections, Expert Opin. Ther. Patents 15, 947-953.
89. Tarantino, P. M.; Zhi, C.; Gambino, J. J.; Wright, G. E.; Brown, N. C. (1999), 6-Anilinouracil-based inhibitors of Bacillus subtilis DNA polymerase III: Antipolymerase and antimicrobial structure-activity relationships based on substitution at uracil N3, J. Med. Chem. 42, 2035-2040.
90. Tarantino, P. M., Jr.; Zhi, C.; Wright, G. E.; Brown, N. C. (1999), Inhibitors of DNA polymerase III as novel antimicrobial agents against gram-positive eubacteria, Antimicrob. Agents Chemother. 43, 1982-1987.
91. Kuhl, A.; Svenstrup, N.; Ladel, C.; Otteneder, M.; Binas, A.; Schiffer, G.; Brands, M.; Lampe, T.; Ziegelbauer, K.; Rubsamen-Waigmann, H.; Haebich, D.; Ehlert, K. (2005), Biological characterization of novel inhibitors of the gram-positiveDNApolymerase IIIC enzyme, Antimicrob. Agents Chemother. 49, 987-995.
92. Butler,M. M., Skow, D. J.; Stephenson, R. O.; Lyden, P. T.; Lamarr,W. A.; Foster, K. A. (2002), Lowfrequencies of resistance among staphylococcus and enterococcus species to the bactericidal DNA polymerase inhibitor N3-hydroxybutyl 6-(30-ethyl-40-methylanilino) uracil, Antimicrob. Agents Chemother. 46, 3770-3775.
93. Butler, M. M.; Lamarr, W. A.; Foster, K. A.; Barnes, M. H.; Skow, D. J.; Lyden, P. T.; Kustigian, L. M.; Zhi, C.; Brown, N. C.; Wright, G. E.; Bowlin, T. L. (2007), Antibacterial activity and mechanism of action of a novel anilinouracil:fluoroquinolone hybrid compound, Antimicrob. Agents Chemother. 51, 119-127.
94. Wright, G.; Brown, N.; Xu,W.-C.; Long, Z.-Y.; Zhi, C.; Gambino, J.; Barnes, M.; Butler, M. (2005), Active site directed inhibitors of replication-specific bacterial DNA polymerases, Bioorg. Med. Chem. Lett. 15, 729-732.
95. Heath, R. J.; White, S. W.; Rock, C. O. (2002), Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics, Appl. Microbiol. Biotechnol. 58, 695-703.
96. Heath, R. J.; Rock, C. O. (2004), Fatty acid biosynthesis as a target for novel antibacterials, Curr. Opin. Invest. Drugs 5, 146-153.
97. Heath, R. J.; Rock, C. O. (2000), Microbiology: A triclosan-resistant bacterial enzyme, Nature 406, 145-146.
98. Massengo-Tiassé, R. P.; Cronan, J. E. (2008), Vibrio cholerae FabV defines a newclass of enoyl-acyl carrier protein reductase, J. Biol. Chem. 283, 1308-1316.
99. Zhu, L.; Lin, J.; Ma, J.; Cronan, J. E.; Wang, H. (2010), The triclosan resistance of Pseudomonas aeruginosa PA01 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase, Antimicrob. Agents Chemother. 54, 689-898.
100. Heath, R. J.; Su, N.; Murphy, C. K.; Rock, C. O. (2000), The enoyl-[acyl-carrier-protein] reductases FabI and FabL from Bacillus subtilis, J. Biol. Chem. 275, 40128-40133.
101. Heerding, D. A.; Chan, G.; Dewolf, W. E.; Fosberry, A. P.; Janson, C. A.; Jaworski, D. D.; Mcmanus, E.; Miller, W. H.; Moore, T. D.; Payne, D. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Smith,W.; Takata, D. T.; Vaidya, K. S.; Yuan, C. C.; Huffman,W. F. (2001), 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI), Bioorg. Med. Chem. Lett. 11, 2061-2065.
102. Payne, D. J.; Miller,W. H.; Berry, V.; Brosky, J.; Burgess,W. J.; Chen, E.; Dewolf,W. E., Jr.; Fosberry,A. P.; Greenwood, R.; Head, M. S.; Heerding, D. A.; Janson, C. A.; Jaworski, D. D.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Newlander, K. A.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Salyers, K. L.; Seefeld, M. A.; Smyth, M. G.; Takata, D. T.; Uzinskas, I. N.;Vaidya, K.;Wallis, N. G.;Winram, S. B.;Yuan, C. C. K.; Huffman, W. F. (2002), Discovery of a novel and potent class of FabI-directed antibacterial agents, Antimicrob. Agents Chemother. 46, 3118-3124.
103. Karlowsky, J. A.; Kaplan, N.; Hafkin, B.; Hoban, D. J.; Zhanel, G. G. (2009), AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity, Antimicrob. Agents Chemother. 53, 3544-3548.
104. Bogdanovich, T.; Clark, C.; Kosowska-Shick, K.; Dewasse, B.; Mcghee, P.; Appelbaum, P. C. (2007), Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents, Antimicrob. Agents Chemother. 51, 4191-4195.
105. Escaich, S.; Prouvensier, L.; Saccomani, M.; Durant, L.; Denis, A.; Soulama, C.; Faivre, F.; Bonvin, Y.; Gerusz, V.; Oxoby, M., MUT37307 FabI inhibitor: In vitro and in vivo antibacterial activity against S. aureus, Proc. 48th Interscience Conf. Antimicrobial Agents Chemotherapy, Washington, DC, 2008, Poster F1-333.
106. Brinster, S.; Lamberet, G.; Staels, B.; Trieu-Cuot, P.; Gruss, A.; Poyart, C. (2009), Type II fatty acid synthesis is not a suitable antibiotic target for gram-positive pathogens, Nature 458, 83-86.
107. Brinster, S.; Lamberet, G.; Staels, B.;Trieu-Cuot, P.; Gruss, A.; Poyart, C. (2010), Brinster et al. reply, Nature 463, E4-E4.
108. Balemans,W.; Lounis, N.; Gilissen, R.; Guillemont, J.; Simmen, K.; Andries, K.;Koul, A. (2010), Essentiality of FASII pathway for Staphylococcus aureus, Nature 463, E3-E3.
109. Price, A. C.; Choi, K. H.; Heath, R. J.; Li, Z.; White, S.W.; Rock, C. O. (2001), Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin, Structure and mechanism, J. Biol. Chem. 276, 6551-6559.
110. Young, K.; Jayasuriya, H.; Ondeyka, J. G.; Herath, K.; Zhang, C.; Kodali, S.; Galgoci, A.; Painter, R.; Brown-Driver, V.; Yamamoto, R.; Silver, L. L.; Zheng, Y.; Ventura, J. I.; Sigmund, J.; Ha, S.; Basilio, A.; Vicente, F.; Tormo, J. R.; Pelaez, F.; Youngman, P.; Cully, D.; Barrett, J. F.; Schmatz, D.; Singh, S. B.; Wang, J. (2006), Discovery of FabH/ FabF inhibitors from natural products, Antimicrob. Agents Chemother 50, 519-526.
111. Wang, J.; Soisson, S. M.; Young, K.; Shoop, W.; Kodali, S.; Galgoci, A.; Painter, R.; Parthasarathy, G.; Tang, Y. S.; Cummings, R.; Ha, S.; Dorso, K.; Motyl, M.; Jayasuriya, H.; Ondeyka, J.; Herath, K.; Zhang, C.; Hernandez, L.; Allocco, J.; Basilio, A.; Tormo, J. R.; Genilloud, O.; Vicente, F.; Pelaez, F.; Colwell, L.; Lee, S. H.; Michael, B.; Felcetto, T.; Gill, C.; Silver, L. L.; Hermes, J. D.; Bartizal, K.; Barrett, J.; Schmatz, D.; Becker, J. W.; Cully, D.; Singh, S. B. (2006), Platensimycin is a selective FabF inhibitor with potent antibiotic properties, Nature 441, 358-361.
112. Wang, J.; Kodali, S.; Lee, S. H.; Galgoci, A.; Painter, R.; Dorso, K.; Racine, F.; Motyl, M.; Hernandez, L.; Tinney, E.; Colletti, S. L.; Herath, K.; Cummings, R.; Salazar, O.; Gonzalez, I.; Basilio, A.; Vicente, F.; Genilloud, O.; Pelaez, F.; Jayasuriya, H.; Young, K.; Cully, D. F.; Singh, S. B. (2007), Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties, Proc. Natl. Acad. Sci. USA 104, 7612-7616.
113. Singh, S. B.; Ondeyka, J. G.; Herath, K. B.; Zhang, C.; Jayasuriya, H.; Zink, D. L.; Parthasarathy, G.; Becker, J. W.; Wang, J.; Soisson, S. M. (2009), Isolation, enzymebound structure and antibacterial activity of platencin A1 from Streptomyces platensis, Bioorg. Med. Chem. Lett 19, 4756-4759.
114. Lu, X.; You, Q. (2010), Recent advances on platensimycin: A potential antimicrobial agent, Curr. Med. Chem 17, 1139-1155.
115. Nicolaou, K. C.; Stepan, A. F.; Lister, T.; Li, A.; Montero, A.; Tria, G. S.; Turner, C. I.; Tang, Y.; Wang, J.; Denton, R. M.; Edmonds, D. J. (2008), Design, synthesis, and biological evaluation of platensimycin analogues with varying degrees of molecular complexity, J. Am. Chem. Soc. 130, 13110-13119.
116. Hitchings, G. H.; Burchall, J. J. (1965), Inhibition of folate biosynthesis and function as a basis for chemotherapy, Adv. Enzymol. Relat. Areas Mol. Biol. 27, 417-468.
117. Then, R. L., Quantitative aspects of synergistic combinations of antibacterial agents, in Brumfitt,W.; Curcio, L.; Silvestri, L., eds., Combined Antimicrobial Therapy, Martinus Nijhoff, The Hague, 1979, pp. 151-168.
118. Lacey, R.W.; Gunasekera, H. K.W.; Lord, V.; Leiberman, P. J.; Luxton, D. E. A. (1980), Comparison of trimethoprim alone with trimethoprim sulphamethoxazole in the treatment of respiratory and urinary infections with particular reference to selection of trimethoprim resistance, Lancet 315, 1270-1273.
119. Pearson, N. J.; Mcsherry, A.; Towner,K. J.; Cattell,W. R.; O'grady, F. (1979), Emergence of trimethoprim-resistant enterobacteria in patients receiving long-term co-trimoxazole for the control of intractable urinary-tract infection, Lancet 314, 1205-1209.
120. Hevener,K. E.;Yun, M. K.; Qi, J.;Kerr, I. D.; Babaoglu, K.; Hurdle, J. G.; Balakrishna, K.; White, S. W.; Lee, R. E. (2010), Structural studies of pterin-based inhibitors of dihydropteroate synthase, J. Med. Chem. 53, 166-177.
121. Lever, O. W., Jr.; Bell, L. N.; Hyman, C.; Mcguire, H. M.; Ferone, R. (1986), Inhibitors of dihydropteroate synthase: Substituent effects in the side-chain aromatic ring of 6-[[3-(aryloxy)propyl]amino]-5-nitrosoisocytosines and synthesis and inhibitory potency of bridged 5-nitrosoisocytosine-p-aminobenzoic acid analogues, J. Med. Chem. 29, 665-670.
122. Lever, O. W., Jr.; Bell, L. N.; Mcguire, H. M.; Ferone, R. (1985), Monocyclic pteridine analogues. Inhibition of Escherichia coli dihydropteroate synthase by 6-amino-5-nitrosoisocytosines, J. Med. Chem. 28, 1870-1874.
123. Babaoglu, K.; Qi, J.; Lee, R. E.; White, S. W. (2004), Crystal structure of 7,8-dihydropteroate synthase from Bacillus anthracis: Mechanism and novel inhibitor design, Structure 12, 1705-1717.
124. Bennett, B. C.; Xu, H.; Simmerman, R. F.; Lee, R. E.; Dealwis, C. G. (2007), Crystal structure of the anthrax drug target, Bacillus anthracis dihydrofolate reductase, J. Med. Chem. 50, 4374-4381.
125. Furano, A.V. (1978), Direct demonstration of duplicate tuf genes in enteric bacteria, Proc. Natl. Acad. Sci. USA 75, 3104-3108.
126. Filer, D.; Furano, A. V. (1981), Duplication of the tuf gene, which encodes peptide chain elongation factorTu, iswidespread ingram-negative bacteria, J.Bacteriol.148, 1006-1011.
127. Parmeggiani, A.; Nissen, P. (2006), Elongation factor Tu-targeted antibiotics: Four different structures, two mechanisms of action, FEBS Lett. 580, 4576-4581.
128. Zuurmond, A. M.; Olsthoorn-Tieleman, L. N.; Martien De Graaf, J.; Parmeggiani, A.; Kraal, B. (1999), Mutant EF-Tu species reveal novel features of the enacyloxin IIa inhibition mechanism on the ribosome, J. Mol. Biol. 294, 627-637.
129. Landini, P.; Bandera, M.; Soffientini, A.; Goldstein, B. P. (1993), Sensitivity of elongation factor Tu (EF-Tu) from different bacterial species to the antibiotics efrotomycin, pulvomycin and MDL 62879, J. Gen. Microbiol. 139, 769-774.
130. Morris, R. P.; Leeds J. A.; Naegeli, H. U.; Oberer, L.; Memmert, K.;Weber, E.; Lamarche, M. J.; Parker, C. N.; Burrer, N.; Esterow, S.; Hein, A. E.; Schmitt, E. K.; Krastel, P. (2009), Ribosomally synthesized thiopeptide antibiotics targeting elongation factor Tu, J. Am. Chem. Soc. 131, 5946-5955.
131. Parmeggiani, A.; Krab, I. M.; Okamura, S.; Nielsen, R. C.; Nyborg, J.; Nissen, P. (2006), Structural basis of the action of pulvomycin and GE2270 A on elongation factor Tu, Biochemistry 45, 6846-6857.
132. Zeef, L. A.; Bosch, L.; Anborgh, P. H.; Cetin, R.; Parmeggiani, A.; Hilgenfeld, R. (1994), Pulvomycin-resistant mutants of E.coli elongation factor Tu, EMBO J. 13, 5113-5120.
133. Thomaides, H. B.; Davison, E. J.; Burston, L.; Johnson, H.; Brown, D. R.; Hunt, A. C.; Errington, J.; Czaplewski, L. (2007), Essential bacterial functions encoded by gene pairs, J. Bacteriol. 189, 591-602.
134. Nitiss, J.; Wang, J. C. (1988), DNA topoisomerase-targeting antitumor drugs can be studied in yeast, Proc. Nal. Acad. Sci. USA 85, 7501-7505.
135. Typas, A.; Nichols, R. J.; Siegele, D. A.; Shales, M.; Collins, S. R.; Lim, B.; Braberg, H.; Yamamoto, N.; Takeuchi, R.; Wanner, B. L.; Mori, H.; Weissman, J. S.; Krogan, N. J.; Gross, C. A. (2008), High-throughput, quantitative analyses of genetic interactions in E. coli, Nature Meth. 5, 781-787.
136. Barbachyn, M. R., Recent advances in the discovery of hybrid antibacterial agents. in Macor, J. E. ed., Annual Reports Medicinal Chemistry, Academic Press, 2008, pp. 281-290.
137. Bremner, J. B.; Ambrus, J. I.; Samosorn, S. (2007), Dual action-based approaches to antibacterial agents, Curr. Med. Chem. 14, 1459-1477.
138. Long, D. D.; Marquess, D. G. (2009), Novel heterodimer antibiotics: A review of recent patent literature, Future Med. Chem. 1, 1037-1050.
139. Robertson, G. T.; Bonventre, E. J.; Doyle, T. B.; Du, Q.; Duncan, L.; Morris, T. W.; Roche, E. D.; Yan, D.; Lynch, A. S. (2008), In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: Studies of the mode of action in Staphylococcus aureus, Antimicrob. Agents Chemother. 52, 2313-2323.
140. Gordeev, M. F.; Hackbarth, C.; Barbachyn, M. R.; Banitt, L. S.; Gage, J. R.; Luehr, G.W.; Gomez, M.; Trias, J.; Morin, S. E.; Zurenko, G. E.; Parker, C. N.; Evans, J. M.; White, R. J.; Patel, D. V. (2003), Novel oxazolidinone-quinolone hybrid antimicrobials, Bioorg. Med. Chem. Lett. 13, 4213-4216.
141. Hubschwerlen, C.; Specklin, J.-L.; Baeschlin, D. K.; Borer, Y.; Haefeli, S.; Sigwalt, C.; Schroeder, S.; Locher, H. H. (2003), Structure-activity relationship in the oxazolidinonequinolone hybrid series: Influence of the central spacer on the antibacterial activity and the mode of action, Bioorg. Med. Chem. Lett. 13, 4229-4233.
142. Hubschwerlen, C.; Specklin, J.-L.; Sigwalt, C.; Schroeder, S.; Locher, H. H. (2003), Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids, Bioorg. Med. Chem. Lett. 11, 2313-2319.
143. Zhi,C.;Long,Z.Y.;Manikowski,A.;Comstock, J.;Xu,W.C.;Brown,N.C.;Tarantino,P.M., Jr.; Holm, K. A.; Dix, E. J.; Wright, G. E.; Barnes, M. H.; Butler, M. M.; Foster, K. A.; Lamarr,W.A.;Bachand,B.;Bethell,R.;Cadilhac,C.;Charron,S.;Lamothe,S.;Motorina, I.; Storer, R. (2006), Hybrid antibacterials, DNA polymerase-topoisomerase inhibitors, J. Med. Chem. 49, 1455-1465.
144. Pokrovskaya, V.; Belakhov, V.; Hainrichson, M.; Yaron, S.; Baasov, T. (2009), Design, synthesis, and evaluation of novel fluoroquinolone aminoglycoside hybrid antibiotics, J. Med. Chem. 52, 2243-2254.
145. Asahina, Y.; Nagae, O.; Sato, T.; Takadoi, M.; Ohata, K.; Shibue, T.; Takano, H.; Nishimura, A.; Shibata, T.; Ban, S.; Kurasaki, H.; Yokota, K.; Katayama, S.; Kiyota, K.; Nagata, E.; Watanabe, K.; Eguchi, T.; Ushiwata, M.; Fukuda, Y., AM-3005: Synthesis and in vitro antibacterial activity of novel mutilin-quinolone hybrid antibacterial agent, Proc. 48th Interscience Conf. Antimicrobial Agents Chemotherapy, Washington, DC., 2008, Poster F1-2030.
146. Ebisu, H.; Yamaguchi, Y.; Ueda, R.; Kishii, R.; Takei, M., AM-3005: A novel mutilinquinolone hybrid antibiotic with potent activity against MRSA, Proc. 48th Interscience Conf. Antimicrobial Agents Chemotherapy, Washington, DC, 2008, Poster F1-2031.
147. Yamaguchi, Y.; Ebisu, H.; Ueda, R.; Kishii, R.; Takei, M., AM-3005: A novel mutilinquinolone hybrid, possesses potent inhibitory activity against protein synthesis with a type II topoisomerase inhibition, Proc. 48th Interscience Conf. Antimicrobial Agents Chemotherapy, Washington, DC, 2008, Poster F1-2032.
148. Leuthner, K. D.; Vidaillac, C.; Cheung, C. M.; Rybak, M. J. (2010), In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin nonsusceptible staphylococci isolates, Antimicrob. Agents Chemother. 54, 3799-3803.
149. Long, D. D.; Aggen, J. B.; Chinn, J.; Choi, S. K.; Christensen, B. G.; Fatheree, P. R.; Green, D.; Hegde, S. S.; Judice, J. K.; Kaniga, K.; Krause, K. M.; Leadbetter, M.; Linsell, M. S.; Marquess, D. G.; Moran, E. J.; Nodwell, M. B.; Pace, J. L.; Trapp, S. G.; Turner, S. D. (2008), Exploring the positional attachment of glycopeptide/beta-lactam heterodimers, J. Antibiot. (Tokyo) 61, 603-614.
150. Long, D. D.; Aggen, J. B.; Christensen, B. G.; Judice, J. K.; Hegde, S. S.; Kaniga, K.; Krause, K. M.; Linsell, M. S.; Moran, E. J.; Pace, J. L. (2008), A multivalent approach to drug discovery for novel antibiotics, J. Antibiot. (Tokyo) 61, 595-602.
151. Krause, K. M.; Difuntorum, S.; Blais, J.; Turner, S. D.; Marquess, D. (2007), TD-1792, a new antibiotic with improved in vitro activity, Proc. 47th Interscience Conf. Antimicrobial Agents Chemotherapy, Chicago, Poster E-1626.
152. Difuntorum, S.; Blais, J.; Hegde, S.; Skinner, R.; Reyes, N.; Trumball, J.; Turner, S. D.; Marquess, D., In vitro and in vivo evidence for a multivalent mode of action of TD-1792 against Staphylococcus aureus, Proc. 47th Interscience Conf. Antimicrobial Agents Chemotherapy, Chicago, 2007, Poster F1-2110.
153. Stryjewski, M.; Barriere, S.; Kitt, M.; Corey, R., TD-1792 vs. vancomycin for treatment of complicated gram positive skin and structure infections (cSSSI), Proc. 47th Interscience Conf. Antimicrobial Agents Chemotherapy, Chicago, 2007, Poster L-1147a.